Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
First Claim
Patent Images
1. A method for producing a composition comprising the steps of:
- a) selecting and culturing a Lactobacillus strain;
b) obtaining a cell-free culture supernatant from said strain;
c) evaluating the level of TNF-alpha in the supernatant using a model system, wherein a reduction in the level of TNF-alpha identifies a lactic acid bacteria strain;
d) selecting said lactic acid bacteria strain; and
e) producing a composition comprising either cells of the strain selected in d) or a Helicobacter pylori associated inflammation-reducing component derived from the cell-free culture supernatant of said strain,f) wherein the composition is for administration to a mammal for reducing gastrointestinal inflammation associated with Helicobacter pylori infection in the gastrointestinal tract of said mammal.
1 Assignment
0 Petitions
Accused Products
Abstract
Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.
12 Citations
10 Claims
-
1. A method for producing a composition comprising the steps of:
-
a) selecting and culturing a Lactobacillus strain; b) obtaining a cell-free culture supernatant from said strain; c) evaluating the level of TNF-alpha in the supernatant using a model system, wherein a reduction in the level of TNF-alpha identifies a lactic acid bacteria strain; d) selecting said lactic acid bacteria strain; and e) producing a composition comprising either cells of the strain selected in d) or a Helicobacter pylori associated inflammation-reducing component derived from the cell-free culture supernatant of said strain, f) wherein the composition is for administration to a mammal for reducing gastrointestinal inflammation associated with Helicobacter pylori infection in the gastrointestinal tract of said mammal. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification